No Data
Summary of Beijing Balance Medical Technology Co., Ltd.'s 2024 semi-annual report
beijing balance medical technology co., ltd. 2024 semi-annual report
Beijing Balance Medical Technology Co., Ltd. (688198.SH) reported a net income of 35.1907 million yuan in the first half of the year, a decrease of 20.42% compared to the same period last year.
Beijing Balance Medical Technology Co., Ltd. (688198.SH) announced its semi-annual report for 2024, achieving revenue of 0.191 billion yuan during the reporting period, a year-on-year growth of 13.74%; net income attributable to shareholders of the listed company was 35.1907 million yuan, a year-on-year decrease of 20.42%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 32.564 million yuan, a year-on-year decrease of 14.04%; basic earnings per share was 0.26 yuan. In the first half of 2024, the market environment continued to face pressure from the macroeconomic situation and medical insurance payments, but the surgical volume in the company's product application field continued to increase.
Bairen Medical (688198.SH) 2023 equity distribution: 0.80 yuan per share, share registration on May 27
Bairen Medical (688198.SH) issued the 2023 equity distribution implementation notice. This time, profits are distributed to Israel...
Bairen Healthcare (688198.SH): Net profit of 8.319,800 yuan in the first quarter decreased by 28.88% year-on-year
Gelonghui, April 22丨Bairen Healthcare (688198.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 76.265,200 yuan, up 17.53% year on year; net profit attributable to shareholders of listed companies was 8.3198 million yuan, down 28.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.3778 million yuan, down 29.26% year on year; basic earnings per share were 0.06 yuan.
Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention
Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.
No Data
